Overview

GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Docetaxel